This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Albireo Pharma (ALBO *) Stock Overview

ALBO * fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 51.14% per year

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

ALBO * Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Albireo Pharma, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Albireo Pharma
Historical stock prices
Current Share Price	US$827.95
52 Week High	US$493.83
52 Week Low	US$382.76
Beta	1.04
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	48.59%

Recent updates

Shareholder Returns

	ALBO *	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	n/a	0%	0%

Return vs Industry: Insufficient data to determine how ALBO * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how ALBO * performed against the MX Market.

Price Volatility

Is ALBO *'s price volatile compared to industry and market?
ALBO * volatility
ALBO * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: ALBO * has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ALBO *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	130	Ron Cooper	www.albireopharma.com

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases.

Albireo Pharma, Inc. Fundamentals Summary

How do Albireo Pharma's earnings and revenue compare to its market cap?
ALBO * fundamental statistics
Market cap	Mex$16.70b
Earnings (TTM)	-Mex$2.38b
Revenue (TTM)	Mex$1.04b

16.1x

P/S Ratio

-7.0x

P/E Ratio

Is ALBO * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALBO * income statement (TTM)
Revenue	US$57.39m
Cost of Revenue	US$2.55m
Gross Profit	US$54.84m
Other Expenses	US$185.99m
Earnings	-US$131.14m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-6.29
Gross Margin	95.56%
Net Profit Margin	-228.51%
Debt/Equity Ratio	0%

How did ALBO * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/03/03 00:58
End of Day Share Price	2023/01/29 00:00
Earnings	2022/09/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Albireo Pharma, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
null null	Guggenheim Securities, LLC
Seamus Fernandez	Guggenheim Securities, LLC

Albireo Pharma, Inc.BMV:ALBO * Stock Report